Combined plasmapheresis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: A case report

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 4, 2003, Pages 395-399

  Koschmieder, Steffen ^a,b   Miesbach, Wolfgang ^a   Fauth, Florian ^a   Bojunga, Joerg ^a   Scharrer, Inge ^a   Brodt, Hans Reinhard ^a  

^a GOETHE UNIVERSITY   (Germany)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Acute respiratory distress syndrome; Catastrophic antiphospholipid syndrome; Multimodal treatment; Myocardial infarction; Plasmapheresis

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; LOW MOLECULAR WEIGHT HEPARIN; MEPREDNISONE; NADROPARIN; NORADRENALIN; PHOSPHOLIPID ANTIBODY; TAZOBACTAM;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANAMNESIS; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRONCHITIS; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER FLOWMETRY; DRUG INDICATION; FEMALE; FOOT; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; LABORATORY TEST; LUNG FUNCTION TEST; LUNG INFILTRATE; PLASMAPHERESIS; PRIORITY JOURNAL; SEPTIC SHOCK; SKIN MANIFESTATION; TERMINAL DISEASE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; X RAY ANALYSIS;

ACUTE DISEASE; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; GLYCOPROTEINS; HEPARIN; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSION; INJECTIONS, INTRAVENOUS; INTERNATIONAL NORMALIZED RATIO; METHYLPREDNISOLONE; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; RESPIRATORY INSUFFICIENCY; TIME FACTORS; VENOUS THROMBOSIS;

EID: 0037495133     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200306000-00011     Document Type: Article

References (16)

1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-1311.
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752-763.
3. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15:145-151.
4. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90:29-37.
5. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19:508-512.
6. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77:195-207.
7. Asherson RA, Cervera R, Pierre JC, Shoenfeld Y, Espinosa G, Petri MA, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80:355-377.
8. Vaphiades MS, Brock W, Brown HH, Petursson G, Westfall CT. Catastrophic antiphospholipid antibody syndrome manifesting as an orbital ischemic syndrome. J Neuroophthalmol 2001; 21:260-263.
9. Triplett DA, Asherson RA. Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Hematol 2000; 65:154-159.
10. Flamholz R, Tran T, Grad GI, Mauer AM, Olopade OI, Ellman MH, et al. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome:beta(2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apheresis 1999; 14:171-176.
11. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987; 57:144-147.
12. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74:1185-1190.
13. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177-185.
14. Erkan D, Zhang HW, Shriky RC, Merrill JT. Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002; 11:215-220.
15. Neuwelt CM, Daikh DI, Linfoot JA, Pfister DA, Young RG, Webb RL, et al. Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years. Arthritis Rheum 1997; 40:1534-1539.
16. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - molecular mimicry? J Rheumatol 2000; 27:12-14.